Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00999622
Other study ID # NABTT-0305 CDR0000363636
Secondary ID U01CA062475NABTT
Status Completed
Phase N/A
First received October 21, 2009
Last updated May 24, 2012
Start date July 2004

Study information

Verified date May 2012
Source Sidney Kimmel Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

RATIONALE: Gathering information over time from laboratory tests of patients with newly diagnosed malignant supratentorial astrocytoma may help doctors learn more about the effect of treatment on white blood cell count and the risk of infection.

PURPOSE: This clinical trial is studying blood samples and risk of infection in patients with newly diagnosed malignant supratentorial astrocytoma.


Description:

OBJECTIVES:

- Determine the frequency and severity of decreases in CD4 counts as a function of therapy in patients with newly diagnosed malignant astrocytoma.

- Determine whether the decrease in CD4 counts is a significant predictor of infections or adverse outcomes in these patients.

OUTLINE: This is a multicenter study.

Patients undergo monthly collection of blood for serial CD4 counts and heme-8 with differential for 1 year for quantitative analysis. Patients also complete a monthly questionnaire about infections and antibiotic use.

Patients are followed every 2 months.

PROJECTED ACCRUAL: A total of 125 patients (100 with high-grade disease and 25 with low-grade disease) will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed primary malignant brain tumor in 1 of the following groups:

- High grade (grade III or IV) supratentorial glioma receiving antineoplastic treatment and with 1 of the following histologies:

- Anaplastic astrocytoma

- Glioblastoma multiforme (giant cell glioblastoma or gliosarcoma)

- Anaplastic oligodendroma

- Low grade (grade I or II) supratentorial glioma not planning to receive treatment of any kind (including steroids) and with 1 of the following histologies:

- Astrocytoma

- Oligodendroglioma

PATIENT CHARACTERISTICS:

- Karnofsky performance status 60-100%

- No HIV positivity

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy for brain tumor except polifeprosan 20 with carmustine implant (GliadelĀ® wafer)

- No prior cranial radiotherapy or radiotherapy for brain tumor

- No prior immunotherapy or biologic agents for brain tumor, including any of the following:

- Immunotoxins

- Immunoconjugates

- Peptide receptor antagonists

- Interleukins

- Interferons

- Tumor-infiltrating lymphocytes

- Lymphokine-activated killer cell therapy

- Gene therapy

- Antisense therapy

- No prior hormonal therapy for brain tumor

- More than 14 days since prior and no concurrent steroid therapy for patients with low-grade (grade I or II) astrocytoma

- Prior glucocorticoid therapy allowed

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
laboratory biomarker analysis

questionnaire administration


Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center National Cancer Institute (NCI), North American Brain Tumor Consortium

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency and severity of decreases in CD4 counts 1 year Yes
Primary Determination of decrease in CD4 counts as significant predictor of infections or adverse outcomes 1 year No
See also
  Status Clinical Trial Phase
Completed NCT04529421 - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting NCT00342589 - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Withdrawn NCT04217252 - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection N/A
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Withdrawn NCT02904434 - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting NCT02768454 - Antimicrobials Stewardship by Pharmacist N/A
Completed NCT02219776 - Decreasing Infection In Arthroscopic Shoulder Surgery N/A
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Recruiting NCT02098226 - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts N/A
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Completed NCT01434797 - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Terminated NCT01441206 - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants Phase 1
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A